



# Clinical chameleons: an emergency medicine focused review of carbon monoxide poisoning

Patrick Chow Yuen Ng<sup>1</sup> · Brit Long<sup>2</sup> · Alex Koyfman<sup>3</sup>

Received: 25 July 2017 / Accepted: 1 February 2018 / Published online: 12 February 2018  
© SIMI 2018

## Abstract

Carbon monoxide (CO) is a colorless, odorless gas that is found in the environment, in the home, and in the human body as a normal part of mammalian metabolism. Poisoning from CO, a common exposure, is associated with significant morbidity and mortality if not recognized and treated in a timely manner. This review evaluates the signs and symptoms of CO poisoning, conditions that present similar to CO poisoning, and an approach to the recognition and management for CO poisoning. CO poisoning accounts for thousands of emergency department visits annually. If not promptly recognized and treated, it leads to significant morbidity and mortality. CO poisoning poses a challenge to the emergency physician because it classically presents with non-specific symptoms such as headache, dizziness, nausea, and vomiting. Due to nonspecific presentations, it is easily mistaken for other, more benign diagnoses such as viral infection. The use of specific historical clues such as exposure to non-conventional heat sources or suicide attempts in garages, as well as the use of targeted diagnostic testing with CO-oximetry, can confirm the diagnosis of CO poisoning. Once diagnosed, treatment options range from observation to the use of hyperbaric oxygen. CO poisoning is an elusive diagnosis. This review evaluates the signs and symptoms CO poisoning, common chameleons or mimics, and an approach to management of CO poisoning.

**Keywords** Carbon monoxide · Headache · Chameleon · Vomiting · Hyperbaric oxygen

## Introduction

Carbon monoxide (CO) is a colorless, odorless gas produced by the burning of fuels and organic material [1, 2]. It is also produced in low amounts as a byproduct of normal human metabolism. According to the CDC's *Clinical*

*Guidance for Carbon Monoxide (CO) Poisoning After a Disaster* online resource, a normal carboxyhemoglobin (COHb) concentration in the body is less than 2% [3]. This number can increase up to 9–15% in heavy smokers; however, this upper limit in smokers is not well established [1]. CO is also produced by the burning of fuels. Exposures to high levels of CO can occur in building fires, in industrial plants; in garages with vehicle engines running, from charcoal briquettes, from boat propulsion engines; or in the home from malfunctioning gas stoves, heating appliances, or generators. Other sources include forklifts, zambonis, indoor tractor pulls, and concrete saws powered by gas [2–4].

CO poisoning is an important condition in emergency medicine, as it is a common exposure that leads to significant morbidity and mortality [5]. According to the Centers for Disease Control and Prevention (CDC), more than 20,000 emergency department (ED) visits per year are related to CO poisoning, which occurs more commonly in a patient's residence rather than workplace [6]. CO poisoning is caused by intentional and accidental exposure, and is a leading cause of death [7, 8]. To guide emergency medical treatment of CO poisoning, the American College of

---

✉ Patrick Chow Yuen Ng  
patrickcng1@gmail.com

Brit Long  
brit.long@yahoo.com

Alex Koyfman  
akoyfman8@gmail.com

<sup>1</sup> Medical Toxicology, Rocky Mountain Poison and Drug Center, Denver Health and Hospital, 1391 Speer Blvd, Denver, CO 80204, USA

<sup>2</sup> Department of Emergency Medicine, San Antonio Military Medical Center, 3841 Roger Brooke Dr, Fort Sam Houston, San Antonio, TX 78234, USA

<sup>3</sup> Department of Emergency Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA

Emergency Physicians (ACEP) in 2017 published a clinical policy for CO poisoning [9]. The authors of the ACEP policy performed a systematic review to answer three critical clinical questions, demonstrated in Table 1.

This review discusses this clinical policy and evaluates the literature about CO poisoning. CO poisoning can be an elusive diagnosis, and several dangerous conditions may mimic CO poisoning. This review investigates these mimics, and explores the evidence concerning normobaric oxygen (NBO) and hyperbaric oxygen (HBO) therapy in CO poisoning.

## Discussion

### How does carbon monoxide cause toxicity?

CO interferes with oxygen transport and delivery to cells. It has greater affinity for hemoglobin when compared to oxygen (approximately 230–270 times), thus impairing oxygen transport and delivery in the bloodstream leading to cellular hypoxia [10, 11]. COHb is formed when CO binds to hemoglobin. As the concentration of COHb increases, physiologically it causes a leftward shift of the oxyhemoglobin dissociation curve resulting in decreased oxygen delivery to cells. Thus, even with high partial pressures of oxygen, hemoglobin is unable to effectively deliver oxygen to the cells resulting in an intracellular hypoxia. Additionally, CO increases nitric oxide formation that causes vasodilatation as well as microvascular damage that may partially account for the long-term morbidity. CO binding to myoglobin also causes further myocardial impairment. The toxin can also directly damage cells through intracellular protein binding, lipid peroxidation, mitochondrial oxidation, apoptosis, and inflammation [12–18]. Morbidity initially involves systems with high oxygen requirements, most commonly the cardiovascular and neurological systems [13–18]. More specifically, CO poisoning can lead to deadly dysrhythmias and

permanent neurological sequelae if not promptly recognized and managed [13, 19].

### How does a patient exposed to carbon monoxide present?

Patients with CO poisoning may present with a variety of non-specific symptoms, with headache being one of the most commonly reported (Table 2) [11–15]. Other symptoms such as nausea, vomiting, dizziness, weakness, or confusion are also commonly reported [12–35]. Less common presentations include syncope, chest pain, dysrhythmias, neurological deficits that can present similar to stroke, dysrhythmia and dyspnea, as well as fatigue [12–35]. Skin findings such as pallor and cherry red color have been reported [30, 31]. Ernst et al. describe the frequency of presenting symptoms in patients with CO poisoning [8]. In their study, the most common symptoms in descending order are headache, dizziness and weakness. Neurologic findings including faltering concentration, disturbance of memory, emotional changes, stupor, coma, gait difficulty, and movement disorders have also been reported [20–28]. The symptoms are often non-specific, and at times can be mistaken for other conditions.

**Table 2** Frequency of presenting symptoms in patients with elevated COHb concentrations [10]

| Presenting symptom | Patients presenting with elevated COHb levels ( <i>n</i> = 106) (%) |
|--------------------|---|
| Headache           | 35  |
| Dizziness          | 30  |
| Nausea             | 30  |
| Vomiting           | 24  |
| Altered mentation  | 21  |
| Chest pain         | 12  |
| Fatigue            | 7   |
| Syncope            | 6   |

**Table 1** ACEP clinical policy recommendations for the evaluation and management of CO poisoning in adults [9]

| Management question  | Patient management recommendation   |
|--|---|
| In ED patients with suspected acute CO poisoning, can noninvasive COHb measurement be used to accurately diagnose CO toxicity?                           | Do not use noninvasive COHb measurement (pulse CO oximetry) to diagnose CO toxicity in patients with suspected acute CO poisoning (Level B)   |
| In ED patients diagnosed with acute CO poisoning, does HBO therapy as compared with normobaric oxygen therapy improve long-term neurocognitive outcomes? | Emergency physicians should use HBO or high-flow normobaric therapy for acute CO-poisoned patients. It remains unclear whether HBO therapy is superior to normobaric oxygen therapy for improving long-term neurocognitive outcomes (Level B) |
| In ED patients diagnosed with acute CO poisoning, can cardiac testing be used to predict morbidity or mortality?   | In ED patients with moderate to severe CO poisoning, obtain an ECG and cardiac biomarker levels to identify acute myocardial injury which can predict poor outcome (Level B)  |

## How is carbon monoxide poisoning diagnosed?

Initial suspicion of CO poisoning is obtained via the history and physical examination [20–28]. A history of exposure to CO, such as through a fire, a home heater during the winter, or an enclosed space such as garage should help the emergency physician move CO poisoning/exposure higher in the differential when patients present with non-specific symptoms such as headache, fatigue, nausea, and vomiting. Historical evidence of other people and pets in the household having similar symptoms (e.g. birds or dogs suddenly passing out) at the same time suggest CO exposure [20–28]. However, there are numerous diagnoses that may present similar to CO poisoning. The physician must be aware of these potential clinical chameleons to narrow the differential in cases of potential CO poisoning and direct their diagnostic testing. For example, influenza is a common infection that can present with headache, dizziness, and weakness, which are common symptoms reported in CO poisoning. Some potential historical clues that can help distinguish the diagnosis are specific testing (influenza, co-oximetry) and some signs such as rhinorrhea or cough that are not classically seen with CO poisoning [24]. The differential for other causes of headache, dizziness, and weakness is broad, and includes tick borne illnesses and intracranial infections like abscess, encephalitis, and meningitis [31, 36–75]. Other conditions that may have similar presentations to CO poisoning include vascular pathologies [36, 37, 76, 77]. Endocrinological pathologies such as hypoglycemia and diabetic ketoacidosis may also present similarly. Pregnancy-related disorders including posterior reversible encephalopathy syndrome and eclampsia are also part of this differential. Furthermore, hemoglobinopathies such as sulfhemoglobinemia and methemoglobinemia and exposures to different occupational and environmental gases can present with nonspecific symptoms such as malaise and fatigue, just like CO poisoning [31–35]. Exposures to different chemicals such as hydrocarbons, cyanide, and hydrogen sulfide can also have a presentation similar to CO poisoning as they can also poison the mitochondria [32–35, 78, 79]. In many of these processes, nonspecific symptoms such as headache, dizziness and weakness can characterize the presentation. Fortunately, a careful history, physical examination and laboratory workup can assist the provider in distinguishing CO poisoning from many of these mimics.

The diagnosis of CO poisoning is confirmed by an elevated COHb concentration as measured by a CO-Oximeter [23]. A CO-Oximeter is a device that takes advantage of the unique absorptive properties of various forms of hemoglobin including oxyhemoglobin, deoxyhemoglobin, methemoglobin, and COHb [23]. The specific formulas and algorithms used by each CO-Oximeter differ depending on the manufacturer [22]. Generally, two wavelengths, 660 and 930 nm, are registered

by conventional pulse oximetry. The wavelength of oxyhemoglobin and CO are similar enough that the standard pulse oximeter cannot tell the difference between the two, and therefore, is not reliable to exclude the diagnosis [22, 80]. Newer devices can use other wavelengths in addition to the 660 and 930 nm to help determine the proportion of oxyhemoglobin vs deoxyhemoglobin vs methemoglobin vs COHb; however, some of these devices produce variable results when compared to gold standard measurements [81]. As such, the gold standard remains conventional co-oximetry [80]. With level B evidence, the ACEP clinical policy does not recommend the use of non-invasive COHb measurement to diagnose CO toxicity [9].

A COHb concentration > 2% can be abnormal. However, as mentioned previously, other factors, such as smoking can cause an elevation of baseline COHb concentrations [82]. The COHb concentration must be interpreted in the context of a patient's clinical presentation to help determine if a patient requires specific therapy. There is a wide range of reported baseline COHb concentrations in smokers. Some reports suggest that 5–8% is normal in individuals who smoke regularly, while other reports describe concentrations up to 15% as being expected in patients who smoke regularly [82, 83]. Furthermore, even higher baseline concentrations of COHb have been reported in patients who smoke products other than traditional filtered cigarettes (e.g., hookah, unfiltered products, foreign cigarettes, etc.) [82, 83].

Other diagnostics include an electrocardiogram to assess for dysrhythmias as well as a troponin and creatine kinase to assess for possible cardiac ischemia and rhabdomyolysis, respectively [13]. If certain exposures or medical history suggests involvement of a potential ingestion, one can consider adding acetaminophen and salicylate concentrations. Additionally, chest X-ray study and head computed tomography (CT) may be considered especially in patients with severe CO toxicity due to the potential for severe end organ damage [16–18]. Chest X-ray study may display a variety of findings including ground-glass appearance, perihilar haze, peribronchial cuffing, and edema. A head CT may demonstrate abnormal findings in up to 53% of the patients admitted for CO poisoning [15–18]. Cerebral edema and focal lesions involving the basal ganglia may be found [16]. A pregnancy test should be obtained in females, as a positive result may ultimately change management in a patient poisoned with CO [29]. With Level B recommendations, the 2017 ACEP clinical policy recommends obtaining an ECG and cardiac biomarker levels in ED patients with moderate to severe CO poisoning to identify acute myocardial injury [9].

## Once diagnosed, how is carbon monoxide poisoning treated?

The mainstays of treatment include removal from CO source, and administration of 100% normobaric oxygen or

hyperbaric oxygen [17–20, 23–26]. The elimination half-life of CO varies with the amount of dissolved oxygen in a patient's bloodstream as oxygen and CO competitively bind hemoglobin (Table 3). Some studies suggest HBO should be considered in the patient exhibiting signs of acute, severe CO poisoning (e.g. evidence of major end-organ damage including but not limited to myocardial infarction, altered mental status, neurological deficit, or syncope), CO concentration > 25% or if age > 55 years [1, 74]. In these patients, some suggest that hyperbaric oxygen treatment can reduce rates of delayed neurological sequelae (DNS), which has been measured via scores on various tests including but not limited to digit span, trail making, and story recall [5]. DNS are neurologic deficits that occur following CO poisoning. While the deficits can improve with time, they can also be permanent. Thom et al. report data on a prospective, randomized study in patients with mild to moderate CO poisoning. Patients were treated with NBO or HBO, and neurological sequelae were compared based on treatment group [82]. HBO treatment decreased the incidence of delayed neurological sequelae after CO poisoning in this study population [82]. In contrast, Scheinkestel et al. in 1999 find that HBO therapy does not improve outcomes in their randomized controlled trial assessing neurological sequelae in patients with CO poisoning treated with HBO or NBO. They excluded pregnant patients, children, burn victims, or those patients who refused consent [84]. Annane et al. studied a group of 385 patients with acute CO poisoning and syncope. They report that HBO therapy is not superior to NBO therapy [85]. Hampson et al. report on the effects of HBO therapy vs NBO therapy in the treatment of CO-induced headaches. They find no significant difference in the outcomes of the two treatment groups [86]. As seen, there are conflicting data on the efficacy of HBO therapy in the management of CO poisoning, and this area of management remains controversial.

The 2017 ACEP Clinical Policy on CO Poisoning provides Level B recommendations that HBO therapy or high-flow normobaric therapy should be used for acute CO-poisoned patients, though the effects of HBO versus normobaric therapy on long-term neurocognitive outcomes remain unclear [9]. Consultation with a poison center, expert in hyperbarics or medical toxicologist can

assist the provider in determining if HBO is an appropriate treatment.

Alternatively, induced hypothermia has been explored as part of the treatment strategy for severe acute CO poisoning. Oh et al. perform a retrospective review of 227 patients who were diagnosed with severe CO poisoning [30]. This was defined as a patient who had a history of CO exposure and any of the following: GCS < 9, carboxyhemoglobin concentration > 25%, or S100B protein level > 0.165 µg/L. S100B is a protein that has been reported to be used as a biochemical marker for brain injury in CO poisoning. Fifteen patients were included in their case study. These patients received two HBO treatments and then were cooled to 33 °C. The S100B protein concentrations were measured before and after hypothermia was induced. The investigators report a decrease in the S100B protein concentrations after hypothermia is induced, and patients receiving hypothermia also had good recovery [30]. Hypothermia in CO poisoning has not been extensively studied, nor has it been directly compared to monotherapy with HBO. Thus, any definitive conclusions comparing the efficacy of these two treatment modalities in isolation or in combination cannot be made at this time.

Another important factor to consider is ensuring that the source of the exposure is managed properly. Local authorities can help with this. The approach to addressing potential CO sources in homes varies from department to department. The local health department should be contacted.

## Conclusions

Carbon monoxide poisoning is an elusive diagnosis. Due to the non-specific signs and symptoms which include headache, nausea, fatigue, and chest pain, CO poisoning can be mistaken for other pathologies. A detailed yet targeted history and examination, as well as specific testing with a carboxyhemoglobin level, can assist the emergency physician in making the correct diagnosis. Treatments such as oxygen therapy and hyperbaric oxygen therapy can reduce the elimination half-life of CO in the body and possibly prevent delayed neurologic sequelae.

**Acknowledgements** This manuscript did not utilize any grants, and it has not been presented in abstract form. This clinical review has not been published, it is not under consideration for publication elsewhere, its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. This review does not reflect the views or opinions of the U.S. Government, Department of Defense, U.S. Army, U.S. Air Force, or SAUSHEC EM Residency Program.

**Table 3** Elimination half-life of CO [9]

| Treatment              | Elimination half-life (min) |
|------------------------|-----------------------------|
| Room air               | 240–300                     |
| 100% normobaric oxygen | 60–90                       |
| Hyperbaric oxygen      | 20–30                       |



## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Statement of human and animal rights** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** None.

## References

- Sen S, Peltz C, Beard J (2010) Recurrent carbon monoxide poisoning from cigarette smoking. *Am J Med Sci* 340(5):427–428
- Higgins EA, Fiorica V, Thomas AA, Davis HV (1972) Acute toxicity of brief exposure to HF, HC, NO<sub>2</sub>, and HCN with and without CO. *Fire Technol* 8:120–130
- Workplace safety and health topic: carbon monoxide (CO) dangers in boating (2017) Centers for Disease Control and Prevention. <http://www.cdc.gov/niosh/topics/coboating/>. Accessed 31 Jan 2017
- Hawkes AP, McCammon JB, Hoffman RE (1998) Indoor use of concrete saws and other gas-powered equipment. Analysis of reported carbon monoxide poisoning cases in Colorado. *J Occup Environ Med* 40(1):49–54
- Weaver LK, Hopkins RO, Chan KJ, Churchill S, Elliott CG, Clemmer TP, Orme JF Jr, Thomas FO, Morris AH (2002) Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med* 347:1057–1067
- Igbal S, Clower JH, Boehmer TK, Yip FY, Garbe P (2010) Carbon monoxide-related hospitalizations in the U.S.: evaluation of a web-based query system for public health surveillance. *Public Health Rep* 125(3):423–432
- Swain R, Behera C, Kishore S, Krishna K, Gupta SK (2017) Suicidal asphyxiation by carbon monoxide within a polythene bag. *Med Leg J* 85(1):35–37
- Ernst A, Zibrak JD (1998) Carbon monoxide poisoning. *N Engl J Med* 339:1603–1608
- Wolf SJ, Maloney GE, Shih RD, Shy BD, Brown MD (2017) Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. *Ann Emerg Med* 69:98–107
- Deniz T, Kandis H, Eroglu O, Gunes H, Saygun M, Kara I (2017) Carbon monoxide poisoning cases presenting with non-specific symptoms. *Toxicol Ind Health* 33(1):53–60
- Nager EC, O'Connor RE (1998) Carbon monoxide poisoning from spray paint inhalation. *Acad Emerg Med* 5(1):84–86
- Hardy KR, Thom SR (1994) Pathophysiology and treatment of carbon monoxide poisoning. *J Toxicol Clin Toxicol* 32(6):613–629
- Satran D, Henry CR, Adkinson C, Nicholson CI, Bracha Y, Hendry TD (2005) Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. *J Am Coll Cardiol* 45:1513–1516
- Choi IS (1983) Delayed neurologic sequelae in carbon monoxide intoxication. *Arch Neurol* 40:433–435
- Kwon OY, Chung SP, Ha YR, Yoo IS, Kim SW (2004) Delayed postanoxic encephalopathy after carbon monoxide poisoning. *Emerg Med J* 21:250–251
- Beppu T (2014) The role of MR imaging in assessment of brain damage from carbon monoxide poisoning: a review of the literature. *AJNR Am J Neuroradiol* 35(4):625–631
- Suner S, Jay G (2008) Carbon monoxide has direct toxicity on the myocardium distinct from effects of hypoxia in an ex vivo rat heart model. *Acad Emerg Med* 15(1):59–65
- Lavonas EJ (2007) Carbon monoxide poisoning. In: Shannon M, Borron S, Burns M (eds) *Haddad and Winchester's clinical management of poisoning and drug overdose*. Elsevier, Philadelphia, pp 1297–1307
- Hampson NB, Piantadosi CA, Thom SR, Weaver LK (2012) Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. *Am J Respir Crit Care Med* 186(11):1095–1101
- Macnow TE, Waltzman ML (2016) Carbon monoxide poisoning in children: diagnosis and management in the Emergency Department. *Pediatr Emerg Med Pract* 13(9):1–24
- Hampson NB (2016) Myth busting in carbon monoxide poisoning. *Am J Emerg Med* 34(2):295–297
- Zwart A, Buursma A, van Kampen EJ, Oeseburg B, van der Ploeg PH, Zijlstra WG (1981) A multi-wavelength spectrophotometric method for the simultaneous determination of five haemoglobin derivatives. *J Clin Chem Clin Biochem* 19(7):453–463
- Brunelle JA, Degtiarov AM, Moran RF, Race LA (1996) Simultaneous measurement of total hemoglobin and its derivatives in blood using CO-oximeters: analytical principles; their application in selecting analytical wavelengths and reference methods; a comparison of the results of the choices made. *Scand J Clin Lab Invest Suppl* 224:47–69
- Beigel JH (2008) Influenza. *Crit Care Med* 36:2660–2666
- Tibbles PM, Edlesberg JS (1996) Hyperbaric oxygen therapy. *N Engl J Med* 334:1642–1648
- Piantadosi CA (1999) Diagnosis and treatment of carbon monoxide poisoning. *Respir Care Clin N Am* 5:183–202
- Thom SR, Taber RL, Mendiguren II, Clark JM, Hardy KR, Fisher AB (1995) Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. *Ann Emerg Med* 25:474–480
- Tibbles PM, Perrotta PL (1994) Treatment of carbon monoxide poisoning: a critical review of human outcome studies comparing normobaric oxygen with hyperbaric oxygen. *Ann Emerg Med* 24:269–276
- Elkharrat D, Raphael JC, Korach JM, Jars-Guinestre MC, Chastang C, Harboun C, Gajdos P (1991) Acute carbon monoxide intoxication and hyperbaric oxygen in pregnancy. *Intensive Care Med* 17(5):289–292
- Oh BJ, Im TG, Park E, Min TG, Choi SC (2016) Treatment of acute carbon monoxide poisoning with induced hypothermia. *Clin Exp Emerg Med* 30 3(2):100–104
- Centers for Disease Control and Prevention (2017) Questions & answers: antiviral drugs, 2009–2010 flu season. <http://www.cdc.gov/h1n1flu/antiviral.htm>. Accessed 17 Jan 2017
- Nguyen L, Afshari A, Kahn SA, McGrane S, Summitt B (2017) Utility and outcomes of hydroxocobalamin use in smoke inhalation patients. *Burns* 43(1):107–113
- Liu B, Xue Z, Zhu X, Jia C (2016) Long-term trends (1990–2014), health risks, and sources of atmospheric polycyclic aromatic hydrocarbons (PAHs) in the U.S. *Environ Pollut* 220(Pt B):1171–1179
- Spiteri A (2016) The blue patient. *Emerg Med J* 33(12):896
- Cai Y, Zhang B, Ke W, Feng B, Lin H, Xiao J, Zeng W, Li X, Tao J, Yang Z, Ma W, Liu T (2016) Associations of short-term and long-term exposure to ambient air pollutants with hypertension: a systematic review and meta-analysis. *Hypertension* 68(1):62–70
- Li R, Jiang N, Liu Q, Huang J, Guo X, Liu F, Gao Z (2017) Impact of air pollutants on outpatient visits for acute respiratory outcomes. *Int J Environ Res Public Health* 14(1):47
- Acker SN, Ross JT, Partrick DA, Nadlonek NA, Bronsert M, Bensard DD (2014) Glasgow motor scale alone is equivalent

- to Glasgow Coma Scale at identifying children at risk for serious traumatic brain injury. *J Trauma Acute Care Surg* 77(2):304–309
38. Coureuil M, Lecuyer H, Bourdoulous S, Nassif X (2017) A journey into the brain: insight into how bacterial pathogens cross the blood–brain barriers. *Nat Rev Microbiol* 15(3):149–159
  39. Benson R, Mallick S, Purkait S, Suri V, Haresh KP, Gupta S, Sharma D, Julka PK, Rath GK (2016) Primary pediatric mid-brain lymphoma: report of a rare pediatric tumor in a rare location. *World J Clin Cases* 4(12):419–422
  40. Gilbert AL, Heidary G (2016) Update on the evaluation of pediatric idiopathic intracranial hypertension. *Curr Opin Ophthalmol* 27(6):493–497
  41. Fabrizio C, Lepore L, Chironna M, Angarano G, Saracino A (2017) Dengue fever in travelers and risk of local spreading: case reports from Southern Italy and literature update. *New Microbiol* 40(1):11–18
  42. Inci A, Yildirim A, Duzlu O, Doganay M, Aksoy S (2016) Tick-borne disease in Turkey: a review based on one health perspective. *PLoS Negl Trop Dis* 10(12):e0005021
  43. Parola P, Paddock CD, Raoult D (2005) Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. *Clin Microbiol Rev* 18:719–756
  44. Kon'kova-Reidman AB (2016) Tick-borne neuroinfections: clinical characteristics, immunopathogenesis and new pharmacotherapeutic strategies. *Ter Arkh* 88(11):55–61
  45. Hira V, Rockx B (2017) Human tick-borne encephalitis, the Netherlands. *Emerg Infect Dis* 23(1):169
  46. Elsterova J, Palus M, Sirmarova J, Kopecky J, Niller HH, Ruzek D (2017) Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin. *Ticks Tick Borne Dis* 8(2):253–258
  47. Johnson NJ, Luks AM (2016) High-altitude medicine. *Med Clin N Am* 100(2):357–369
  48. Hoiland RL, Bain AR, Rieger MG, Bailey DM, Ainslie PN (2016) Hypoxemia, oxygen content, and the regulation of cerebral blood flow. *Am J Physiol Regul Integr Comp Physiol* 310(5):R398–R413
  49. Shah NM, Hussain S, Cooke M, O'Hara JP, Mellor A (2015) Wilderness medicine at high altitude: recent developments in the field. *Open Access J Sports Med* 6:319–328
  50. Hao R, Zhang J, Ma Z, Xiao M, Zhou L, Kang N, Liang X, Li F (2016) Takayasu's arteritis presenting with common carotid artery dissection: a rare case report. *Exp Ther Med* 12(6):4061–4063
  51. Daily B, Dassow P, Haynes J, Nashelsky J (2017) Giant cell arteritis: biopsy after corticosteroid initiation. *Am Fam Phys* 95(2):116–117
  52. Hofheinz K, Bertz S, Wacker J, Schett G, Manger B (2017) Fever of unknown origin, giant cell arteritis and aortic dissection. *Z Rheumatol* 76(1):83–86
  53. Cabral AG, Lesczynsky A, Climaco VM, Pereira ER, Marcelino PO, Franco AOC, Almeida DF (2017) Cerebral venous sinuses thrombosis in both transverse sinus and torcula: multistep endovascular treatment and stenting. *Interv Neuroradiol* 23(1):84–89
  54. Smyth A, Ronco C, Garovic VD (2017) Preeclampsia: a cardiovascular syndrome in pregnancy. *Curr Hypertens Rep* 19(2):15
  55. Schmidt KJ, Doshi MR, Holzhausen JM, Natavio A, Cadiz M, Winegardner JE (2016) Treatment of severe alcohol withdrawal. *Ann Pharmacother* 50(5):389–401
  56. Kiss L, Holmes S, Chou CE, Dong X, Ross J, Brown D, Mendenhall B, Coronado V, De Silva D, Rockwood GA, Petrikovics I, Thompson DE (2017) Method development for detecting the novel cyanide antidote dimethyl trisulfide from blood and brain, and its interaction with blood. *J Chromatogr B Anal Technol Biomed Life Sci* 1044–1045:149–157
  57. Sunkara T, Etienne D, Caughey ME, Gaduputi V (2017) Small bowel obstruction secondary to acute pancreatitis. *Gastroenterol Res* 10(1):42–44
  58. Niaz K, Bahadar H, Maqbool F, Abdollahi M (2015) A review of environmental and occupational exposure to xylene and its health concerns. *EXCLI J* 14:1167–1186
  59. Bradford AL, Crider CC, Xu X, Naqvi SH (2017) Predictors of recurrent hospital admission for patients presenting with diabetic ketoacidosis and hyperglycemia hyperosmolar state. *J Clin Med Res* 9(1):35–39
  60. Munro V, Tugwell B, Doucette S, Clarke DB, Lacroix A, Imran SA (2016) Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism. *Clin Endocrinol* 85(2):216–222
  61. Guillermin A, Yan DJ, Perrier A, Marti C (2016) Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. *Arch Med Sci* 12(6):1181–1187
  62. Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S (2016) Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: a randomized, double-blind clinical trial. *Indian J Pharmacol* 48(6):649–653
  63. Bhandary SP, Joseph N, Hofmann JP, Saranteas T, Papadimos TJ (2017) Extracorporeal life support for refractory ventricular tachycardia. *Ann Transl Med* 5(4):73
  64. Anis Munirah MK, Lim WK, Sharifah Ainon IM (2016) Arrhythmogenic right ventricular dysplasia. *Med J Malaysia* 71(6):357–359
  65. Haddad FA, Nadelman RB (2003) Lyme disease and the heart. *Front Biosci* 8:s769–s782
  66. Ben Khelil M, Chkirbene Y, Mlika M, Haouet S, Hamdoun M (2017) Penicillin-induced fulminant myocarditis: a case report and review of the literature. *Am J Forensic Med Pathol* 38(1):29–31
  67. Kea B, Alligood T, Manning V, Raitt M (2016) A review of the relationship of atrial fibrillation and acute coronary syndrome. *Curr Emerg Hosp Med Rep* 4(3):107–118
  68. Ramirez-Arias E, Rosas-Peralta M, Borrayo-Sanchez G, Moreno-Ruiz LA, Arenas-Fonseca JG, Arzola-Covarrubias VM, Santos-Martinez LE, Arizmendi-Urbe E (2017) Pulmonary thromboembolism: recent experience of 4 years at a cardiology hospital. *Rev Med Inst Mex Seguro Soc* 55(1):55–62
  69. Sinha SK, Sachan M, Goel A, Singh K, Mishra V, Jha MJ, Kumar A, Abdali N, Asif M, Razi M, Pandey U, Thakur R, Varma CM, Krishna V (2017) Efficacy and safety of thrombolytic therapy in acute submassive pulmonary embolism: follow-up study. *J Clin Med Res* 9(2):163–169
  70. Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S (2017) Determining prognosis in acute exacerbation of COPD. *Int J Chronic Obstruct Pulmon Dis* 12:467–475
  71. Nielsen VM, Madsen J, Aasen A, Toft-Petersen AP, Lubcke K, Rasmussen BS, Christensen EF (2016) Prehospital treatment with continuous positive airway pressure in patients with acute respiratory failure: a regional observational study. *Scand J Trauma Resusc Emerg Med* 24(1):121
  72. Paraskevas KI, Mikhailidis DP (2017) Abdominal aortic aneurysm repair in England and the United States. *N Engl J Med* 376(10):997–998
  73. Puga AE, Rodriguez SC, Panero BM, Moreira BC, Lopez Almodovar LF (2016) Chronic type A aortic dissection and giant aortic root aneurysm after aortic valve replacement. *Aorta* 4(3):108–110
  74. Raphan T, Cohen B, Xiang Y, Yakushin SB (2016) A model of blood pressure, heart rate, and vaso-vagal responses produced by vestibulo-sympathetic activation. *Front Neurosci* 10:96
  75. Pietrus M, Paprota P, Radziszewska R, Huras H, Ludwin A, Wiechec M, Nocun A, Ossowski P, Knafel A, Kialka M, Klyszewko-Molska J, Pitynski K, Zalustowicz A, Banas T (2015) Carbon monoxide poisoning in pregnant woman. *Przegl Lek* 72(9):482–484

76. Kanamori F, Kawabata T, Muraoka S, Kojima T, Watanabe T, Natano N, Seki Y (2016) Ruptured partially thrombosed anterior inferior cerebellar artery aneurysms: two case reports and review of literature. *Nagoya J Med Sci* 78(4):517–522
77. Jiad E, Gill SK, Krutikov M, Turner D, Parkinson MH, Curtis C, Werring DJ (2017) When the heart rules the head: ischaemic stroke and intracerebral haemorrhage complicating infective endocarditis. *Pract Neurol* 17(1):28–34
78. Haouzi P, Sonobe T, Judenherc-Haouzi A (2016) Developing effective countermeasures against acute hydrogen sulfide intoxication: challenges and limitations. *Ann N Y Acad Sci* 1374(1):29–40
79. Sakai N, Hirose Y, Sato N, Kondo D, Shimada Y, Hori Y (2016) Late metabolic acidosis caused by renal tubular acidosis in acute salicylate poisoning. *Intern Med* 55(10):1315–1317
80. Lim SF, Tan IK (1999) Quantitative determination of methaemoglobin and carboxyhaemoglobin by co-oximetry and effect of anticoagulants. *Ann Clin Biochem* 36:774–776
81. Widdop B (2002) Analysis of carbon monoxide. *Ann Clin Biochem* 39:378–391
82. Thom SR, Taber RL, Mendiguren II, Clark JM, Hardy KR, Fisher AB (1995) Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. *Ann Emerg Med* 25(4):474–480
83. Castleden CM, Cole PV (1975) Carboxy haemoglobin levels of smokers and non-smokers working in the city of London. *Br J Ind Med* 32(2):115–118
84. Scheinkestel CD, Bailey M, Myles PS, Jones K, Cooper DJ, Millar IL, Tuxen DV (1999) Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomized controlled clinical trial. *Med J Aust* 170(5):203–210
85. Annane D, Chadda K, Gajods P, Jars-Guinestre MC, Chevret S, Raphael JC (2011) Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. *Intensive Care Med* 37(3):486–492
86. Hampson NB, Ocak T (2017) Comparison of normobaric vs. hyperbaric oxygen in the relief of carbon monoxide headache pain. *Undersea Hyperb Med* 44(4):331–336